Table 1.
Baseline demographics and patient characteristics
| TNF group (n=20) | Non-TNF group (n=37) | p value | |
|---|---|---|---|
| Female | 13 (65 %) | 26 (70 %) | 0.68 |
| Mean age in years (range) | 12.8 (1–20) | 10.8 (3–19) | 0.13 |
| No. of patients age 1–7 | 3 (15 %) | 9 (24 %) | |
| No. of patients age 8–12 | 5 (25 %) | 12 (32 %) | 0.47 |
| No. of patients age 13–21 | 12 (60 %) | 16 (43 %) | |
| White | 17 (85 %) | 36 (97 %) | 0.08 |
| JIA subtype | |||
| Oligoarticular | 1 (5 %) | 7 (19 %) | 0.22 |
| Polyarticular | 4 (20 %) | 3 (8 %) | |
| Spondyloarthropathy | 14 (70 %) | 20 (54 %) | |
| Unspecified/other | 1 (5 %) | 7 (19 %) | |
| Mean length of disease at enrollment in months (SD) | 6.6 (8.4) | 25.1 (37.5) | 0.03 |
| Comorbidities | |||
| Uveitis | 0 (0 %) | 3 (8 %) | 0.19 |
| Inflammatory bowel disease | 0 (0 %) | 1 (3 %) | 0.46 |
| Psoriasis | 2 (10 %) | 2 (5 %) | 0.52 |
| Immunizations up to date | 20 (100 %) | 35 (95 %) | 0.45 |
| Yearly influenza vaccine received | 10 (50 %) | 17 (46 %) | 0.77 |
| Baseline medications | |||
| None | 0 (0 %) | 3 (8 %) | 0.19 |
| NSAIDs | 19 (95 %) | 33 (89 %) | 0.46 |
| Methotrexate | 2 (10 %) | 0 (0 %) | 0.05 |
| Sulfasalazine | 0 (0 %) | 1 (3 %) | 0.46 |
| Steroids (oral or intra-articular) | 0 (0 %) | 0 (0 %) | |
| Baseline disease activitya,b | |||
| CHAQ disability index | 0.8 (0.5) | 0.3 (0.4) | <0.001 |
| CHAQ pain visual analog scale | 43.1 (28.7) | 27.0 (26.8) | 0.04 |
| Total joint count | 6.2 (4.1) | 1.4 (1.8) | <0.001 |
| Physician global assessment | 5.5 (2.1) | 1.6 (1.5) | <0.001 |
| Baseline serologies | |||
| ANA+ | 9 (45 %) | 18 (49 %) | 0.79 |
| RF+ | 2 (10 %) | 7 (19 %) | 0.08 |
| Anti-CCP+ | 2 (10 %) | 3 (8 %) | 0.23 |
| HLA-B27+ | 5 (25 %) | 8 (22 %) | 0.75 |
| Baseline laboratory valuesa | |||
| WBC (count/nl) | 7.0 (1.5) | 7.5 (2.2) | 0.33 |
| Hemoglobin (gm/dl) | 12.6 (1.3) | 13.1 (0.9) | 0.12 |
| Platelets (count/nl) | 312 (64) | 294 (86) | 0.41 |
| ESR (mm/h) | 18 (26) | 7 (8) | 0.02 |
| IgA (mg/dl) | 141 (71) | 147 (68) | 0.77 |
JIA juvenile idiopathic arthritis, SD standard deviation, NSAIDs nonsteroidal anti-inflammatory drugs, CHAQ childhood health assessment questionnaire, ANA antinuclear antibody, RF rheumatoid factor, CCP cyclic citrullinated peptide, HLA human leukocyte antigen, WBC white blood cell, nl nanoliter, gm gram, dl deciliter, ESR erythrocyte sedimentation rate, mm millimeter, IgA immunoglobulin A, mg milligram
a
Measures reported as mean (SD)
b
CHAQ disease index range, 0–3.0; CHAQ pain visual analog scale range, 0–100; total joint count range, 0–26; physician global assessment range, 0–10